Pages

Biotech Forecasters Are Usually Way Too Optimistic About Drug Sales

Your Message Subject or Title
  MANAGE SUBSCRIPTIONS   |   UNSUBSCRIBE   |   VIEW ONLINE
 
 
Chart of the Day
 
Biotech Forecasters Are Usually Way Too Optimistic About Drug Sales

People who invest in biotech stocks are largely speculating on the future sales of drugs that have yet to be approved for the market.

Unfortunately, the experts who forecasts those sales have a track record of being way too optimistic.

In a new research note, Morgan Stanley's Matthew Harrison and Dr. David Friedman reference a recent study published in Nature magazine that found "estimations are in general >160% of peak sales."

The study — conducted by Myoung Cha, Bassel Rifai and Pasha Sarrah — reviewed the consensus sales forecasts for 260 drugs launched between 2002 and 2011. The data set included over 1,700 analyst forecasts.

"[M]ost consensus forecasts were wrong, often substantially," they found. "And although consensus forecasts improved over time as more information became available, accuracy remained an issue even several years post‐launch."

Some findings:
  • "More than 60% of the consensus forecasts in our data set were either over or under by more than 40% of the actual peak revenue."
  • "Although the overall median of the data set was within 4%, the distribution is wide for both under‐ and overestimated forecasts."
  • "A significant number (53) of consensus forecasts were overly optimistic by more than 160% of the actual peak revenues of the product."
  • "The variance in peak sales estimates was still 45% versus actual peak sales 6 years after the drug has launched, reflecting continued uncertainty even as new information becomes available."


To sum it up, drug forecasters tend to be wrong by a wide margin, overly optimistic, and persistently wrong even years after the drug is launched.

Read »


Also On Markets Today:
Advertisement

cotd biotech revenues

CHART OF THE DAY: Here's Why Investors Pay So Much For Biotech Stocks
cotd global financial assets

CHART OF THE DAY: The Rise Of The $156 Trillion Market For Global Financial Assets
cotd stock market missed returns

CHART OF THE DAY: How A Few Poorly-Timed Trades Can Torpedo Two Decades Of Healthy Returns
Share this: Facebook Facebook Twitter Twitter Digg Digg Reddit Reddit StumbleUpon StumbleUpon LinkedIn LinkedIn
Follow us on Facebook Follow us on Twitter
The email address for your subscription is: nguyenvu1187.love@blogger.com
Change Your Email Address | Unsubscribe | Subscribe | Subscribe to the Markets RSS Feed
Business Insider. 257 Park Avenue South, New York, NY 10010
Terms of Service | Privacy Policy



Share the latest business news with your network:

Share on Facebook
Share on Twitter
Share on Linkedin
Share via email


The email address for your subscription is: nguyenvu1187.love@blogger.com

Manage your email preferences   |   Unsubscribe

Business Insider RSS Feed   |   Terms of Service   |   Privacy Policy

Business Insider. 257 Park Avenue South, New York, NY 10010
Sailthru

0 nhận xét:

Post a Comment